SynthesisInternational journal of hematology2013
IL-10 promoter polymorphism associated with decreased risk of aGvHD after stem cell transplantation: a meta-analysis.
Synthesis in International journal of hematology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 7 citations in OpenAlex.
- Reconstitution and clinical significance of T cell subsets in the early stage after related HLA-mismatched peripheral blood hematopoietic SCT without T-cell depletion in vitro.International journal of clinical and experimental pathology · 2015Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The bulk of evidences indicates that variations in the coding for cytokines or the regulation of their expression may play a role in acute graft-versus-host disease (aGvHD) following allogeneic hematopoietic stem cell transplantation (HSCT). It is unclear whether IL-10 promoter polymorphism is associated with the occurrence of aGvHD in allogeneic HSCT. A systematic search was performed in PubMed and Embase databases and 10 studies were identified for inclusion. Data were extracted and pooled ORs together with 95% CIs were calculated. The pooled result indicated that -592A allele in recipient was significantly associated with reduced risk of moderate aGvHD in HSCT [OR = 0.41 (0.21, 0.79), P = 0.008, I² = 25%]. The same pattern was also obtained from the -819T allele in recipient [OR = 0.38 (0.18, 0.79), P = 0.01, I² = 41%]. Furthermore, we found a significant positive correlation between the -592AA homozygote and lower risk of severe aGvHD in HSCT [OR = 0.54 (0.34, 0.86), P = 0.01, I² = 29%]. The similar result was gained from the -1082A allele in recipient and decreased risk of severe aGvHD [OR = 0.71 (0.52, 0.98), P = 0.04, I² = 19%]. However, there was no significant association between -592A, -819T, or -1082A allele in donor and risk of aGvHD. This meta-analysis suggests that the IL-10 A allele or AA homozygote at -592, T allele at -819 and the A allele at -1082 are associated with reduced risk of aGvHD in allogeneic HSCT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.